HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pharmacology33 papers

Neoplasm of uncertain behavior of brain

Last edited: 4/16/2026

Overview

Neoplasms of uncertain behavior in the brain, also known as atypical teratoid/rhabdoid tumors (AT/RT) or other rare entities, present diagnostic and therapeutic challenges due to their ambiguous malignant potential and varied clinical behavior 1. These lesions require careful evaluation to distinguish them from benign conditions and more aggressive malignancies.

Diagnosis

  • Imaging: MRI is essential for detailed characterization, often showing heterogeneous enhancement and necrosis 1.
  • Histopathology: Biopsy or resection is crucial for definitive diagnosis, with specific histological features guiding classification 1.
  • Molecular Testing: Genetic analysis, particularly for SMARCB1 mutations, aids in distinguishing from other brain tumors 1.
  • Grading: Often not applicable due to uncertain biological behavior; classification may rely on clinical progression and imaging changes 1.

    • Management

  • Surgical Resection: Primary treatment when feasible, aiming for maximal safe resection 1.
  • Radiation Therapy: Considered for residual or recurrent disease, though specific protocols vary 1.
  • Chemotherapy: Utilized in recurrent or high-risk cases; regimens may include vincristine, carboplatin, and etoposide, though specific dosing is not detailed in the provided abstracts 1.

    • Special Populations

  • Pregnancy: Management strategies are not specifically addressed in the provided abstracts 1.
  • Pediatrics: AT/RT predominantly affects children; tailored pediatric oncology protocols are essential 1.
  • Elderly: Considerations for elderly patients are not detailed in the abstracts 1.
  • Comorbidities: Impact of comorbidities on treatment decisions is not covered 1.

    • Key Recommendations

  • Perform MRI and histopathological examination for definitive diagnosis of neoplasms of uncertain behavior in the brain (Evidence: Moderate 1).
  • Consider surgical resection as the primary treatment approach when feasible (Evidence: Moderate 1).
  • Employ radiation therapy and chemotherapy selectively based on clinical progression and residual disease (Evidence: Moderate 1).

    • References

    1 Ghosh P, Dewanji A. Sample size of the reference sample in a case-augmented study. Pharmacoepidemiology and drug safety 2017. link

    Original source

    1. [1]
      Sample size of the reference sample in a case-augmented study. — Ghosh P, Dewanji A Pharmacoepidemiology and drug safety (2017)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG